---
title: Challenges and solutions to superior chimeric antigen receptor-T design and
  deployment for B-cell lymphomas
date: '2023-07-24'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/37488074/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1Rkszs2HVZ2RHP33OibaNFew6VK-LzjJWTD4GwmLlk8B-wCceh&fc=20220923065203&ff=20230725180816&v=2.17.9.post6+86293ac
source: (((leukemia) OR (lymphoma)) OR (myeloma)) AND (Stanford University[Affiliation])
description: Chimeric antigen receptor-T (CAR-T) therapies represent a major breakthrough
  in cancer medicine, given the ex vivo-based technology that harnesses the power
  of one's own immune system. These therapeutics have demonstrated remarkable success
  for relapsed/refractory B-cell lymphomas. Although more than a decade has passed
  since the initial introduction of CAR-T therapeutics for patients with leukaemia
  and lymphoma, there is still significant debate as to where CAR-T therapeutics fit
  into ...
disable_comments: true
---
Chimeric antigen receptor-T (CAR-T) therapies represent a major breakthrough in cancer medicine, given the ex vivo-based technology that harnesses the power of one's own immune system. These therapeutics have demonstrated remarkable success for relapsed/refractory B-cell lymphomas. Although more than a decade has passed since the initial introduction of CAR-T therapeutics for patients with leukaemia and lymphoma, there is still significant debate as to where CAR-T therapeutics fit into ...